Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

NCT05704621 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

124

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Drug Related Neoplasm/Cancer

Interventions

PROCEDURE: secondary cytoreductive surgery
DRUG: chemotherapy

Sponsor

Korea University Guro Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]